Georgia Tech researchers have developed a soft, wireless wearable that uses near-infrared spectroscopy to monitor glymphatic clearance dynamics in a natural home environment. This noninvasive technology offers a cost-eff...

New research from Flinders University suggests that relying on single-night sleep studies for obstructive sleep apnea may lead to misdiagnosis due to significant night-to-night variability. The study advocates for incorp...

A new case report demonstrates that combining the myTAP chairside titratable oral appliance with a mouth shield to enforce nasal breathing can significantly improve outcomes for patients with moderate-to-severe obstructi...

The latest version of the SOMNUM software analyzes polysomnography data to automatically detect and differentiate obstructive, central, and mixed sleep apnea.

New data suggest that targeting the underlying orexin deficiency can improve a broad spectrum of narcolepsy type 1 symptoms, from daytime cognition to nighttime sleep architecture.

The FDA has granted Orphan Drug Designation to Tris Pharma’s TRN-257, an investigational once-nightly, low-sodium oxybate therapy for the treatment of idiopathic hypersomnia. The designation recognizes the potential for...

Phase 3 data on the orexin agonist oveporexton suggests that reducing microsleep frequency offers a more accurate reflection of real-world treatment response than traditional wakefulness tests alone.

The granted patent protects the proprietary oral combination therapy through at least 2040, as the company prepares to launch its Phase 2 dose optimization study.

A newly published study shows that ADX71743, a selective mGlu7 inhibitor, significantly modulates sleep-wake regulation and stress-related neurochemistry in animal models.

Race, age, and other factors are linked to disparities in care for people with narcolepsy.